Efficacy of Antidepressants in the Treatment of Severe Depression: The Place of Mirtazapine
The DOI matches its Crossref record.
Abstract
The effectiveness of the newer antidepressants in comparison to that of the more established agents is frequently questioned. Although selective serotonin reuptake inhibitors (SSRIs) show a high degree of pharmacologic selectivity, this does not seem to translate into improved clinical efficacy. Instead, the clinical effectiveness of the tricyclic agents may be attributable to their dual inhibitory effects on both noradrenergic and serotonergic systems. Accordingly, newer antidepressants with multiple modes of action may prove more effective than serotonin-selective compounds. To assess the relative merits of older and newer antidepressant drugs in severe depression, efficacy findings from the limited number of comparative clinical trials conducted in this patient population were reviewed. A systematic approach was taken, with studies being grouped according to the various characteristics that, in conjunction with standard DSM-IV and International Classification of Diseases, 10th revision, diagnostic criteria, define severe depression, viz. a 17-item Hamilton Rating Scale for Depression score > or = 25, hospitalization, and the presence of psychotic (delusional), melancholic, and endogenous features. The contention that tricyclic antidepressants offer superior efficacy to the SSRIs and the reversible monoamine oxidase inhibitors in the treatment of severe depression is supported by several comparisons of clomipramine with fluoxetine, paroxetine, citalopram, and moclobemide. Venlafaxine also seems to be more effective than fluoxetine in hospitalized patients with melancholic depression. Mirtazapine, a noradrenergic and specific serotonergic antidepressant, displays comparable antidepressant efficacy to clomipramine and amitriptyline in severe depression and seems to be a useful option in this patient population.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Severity classification on the Hamilton depression rating scale
Zimmerman, M., Martinez, J. H., Young, D., Chelminski, I., & Dalrymple, K. (2013) · Journal of Affective Disorders · doi:10.1016/j.jad.2013.04.028 · Cited by 1,199
“In contrast to all of these studies, and the APA guidelines, most pharmacotherapy studies have used a cutoff of 25 on the 17-item HAMD to define severe depression (Dunner et al., 2005; Kasper, 1997; Montgomery et al., 2003; Schmitt et al., 2009; Shelton et al., 2007; Versiani et al., 2005), and this cutoff has been re…”
MethodResultBauer, M., Bschor, T., Pfennig, A., Whybrow, P. C., Angst, J., Versiani, M., Möller, H.-J., WFSBP Task Force on Unipolar Depres, Bauer, M., Bschor, T., et al. (2007) · The World Journal of Biological Psychiatry · doi:10.1080/15622970701227829 · Cited by 477
L??o, H., Hale, A., & D??haenen, H. (2002) · International Clinical Psychopharmacology · doi:10.1097/00004850-200209000-00004 · Cited by 361
Bauer, M., Whybrow, P. C., Angst, J., Versiani, M., Möller, H.-J., & WFSBP Task Force on Treatment Guide (2002) · The World Journal of Biological Psychiatry · doi:10.3109/15622970209150599 · Cited by 346
Sertraline versus other antidepressive agents for depression
Cipriani, A., La Ferla, T., Furukawa, T. A., Signoretti, A., Nakagawa, A., Churchill, R., McGuire, H., & Barbui, C. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006117.pub4 · Cited by 299
Metadata
- Authors
- Kasper, S.
- Venue
- Journal of Clinical Psychopharmacology
- Published
- 1997-04
- Volume
- 17
- Pages
- 19S-28S
- ISSN
- 0271-0749 (ISSN-L)
- OpenAlex
- W2317324607
- Cited by
- 41
- References
- 0
- FWCI
- 2.12
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Efficacy of Antidepressants in the Treatment of Severe Depression: The Place of Mirtazapine. https://app.cochat.ai/papers/10.1097/00004714-199704001-00003
- The paper
- Kasper, S. (1997). Efficacy of Antidepressants in the Treatment of Severe Depression: The Place of Mirtazapine. Journal of Clinical Psychopharmacology. https://doi.org/10.1097/00004714-199704001-00003
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.